Image-guided therapy developer IMRIS announced that its revenues dipped in 2014 (end-December 31).
Revenue for the fiscal year decreased to $28.9 million, compared with $46 million in 2013. Net loss improved to $30.2 million, compared with a net loss of $42 million in 2013.
Fourth-quarter revenue decreased to $9.6 million, compared with $10 million in the same period of 2013, due to the timing of Visius Surgical Theatre installation and delivery. The company's net loss decreased to $6.8 million, compared with $21.6 million in the fourth quarter of 2013.
Jay Miller, IMRIS' president and CEO, said the fourth-quarter revenues were near expectations, and the company remains on track to make further gains. IMRIS also reported a near-record backlog of $116.4 million, which Miller said positions it for growth in 2015.
IMRIS' full-year 2015 revenues, comprised of systems, service, upgrades, and disposables sales, are expected to be in the range of $40 million to $55 million.
